JP2006516098A5 - - Google Patents

Download PDF

Info

Publication number
JP2006516098A5
JP2006516098A5 JP2004562249A JP2004562249A JP2006516098A5 JP 2006516098 A5 JP2006516098 A5 JP 2006516098A5 JP 2004562249 A JP2004562249 A JP 2004562249A JP 2004562249 A JP2004562249 A JP 2004562249A JP 2006516098 A5 JP2006516098 A5 JP 2006516098A5
Authority
JP
Japan
Prior art keywords
seq
acid sequence
iia1
amino acid
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004562249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006516098A (ja
JP4741242B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/038172 external-priority patent/WO2004056308A2/en
Publication of JP2006516098A publication Critical patent/JP2006516098A/ja
Publication of JP2006516098A5 publication Critical patent/JP2006516098A5/ja
Application granted granted Critical
Publication of JP4741242B2 publication Critical patent/JP4741242B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

JP2004562249A 2002-11-26 2003-11-26 新脈管形成を調節するα５β１インテグリンへのキメラ及びヒト化抗体 Expired - Lifetime JP4741242B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42974302P 2002-11-26 2002-11-26
US60/429,743 2002-11-26
PCT/US2003/038172 WO2004056308A2 (en) 2002-11-26 2003-11-26 CHIMERIC AND HUMANIZED ANTIBODIES TO α5β1 INTEGRIN THAT MODULATE ANGIOGENESIS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011000939A Division JP2011120593A (ja) 2002-11-26 2011-01-06 新脈管形成を調節するα５β１インテグリンへのキメラ及びヒト化抗体

Publications (3)

Publication Number Publication Date
JP2006516098A JP2006516098A (ja) 2006-06-22
JP2006516098A5 true JP2006516098A5 (enExample) 2006-11-02
JP4741242B2 JP4741242B2 (ja) 2011-08-03

Family

ID=32681936

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004562249A Expired - Lifetime JP4741242B2 (ja) 2002-11-26 2003-11-26 新脈管形成を調節するα５β１インテグリンへのキメラ及びヒト化抗体
JP2011000939A Pending JP2011120593A (ja) 2002-11-26 2011-01-06 新脈管形成を調節するα５β１インテグリンへのキメラ及びヒト化抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011000939A Pending JP2011120593A (ja) 2002-11-26 2011-01-06 新脈管形成を調節するα５β１インテグリンへのキメラ及びヒト化抗体

Country Status (14)

Country Link
EP (2) EP1575516B1 (enExample)
JP (2) JP4741242B2 (enExample)
KR (2) KR20110140143A (enExample)
CN (1) CN100369930C (enExample)
AU (1) AU2003298783B2 (enExample)
BR (1) BR0316670A (enExample)
CA (1) CA2507099C (enExample)
ES (1) ES2387985T3 (enExample)
MX (1) MXPA05005558A (enExample)
NO (1) NO20053101L (enExample)
NZ (1) NZ540562A (enExample)
RU (1) RU2346701C2 (enExample)
WO (1) WO2004056308A2 (enExample)
ZA (1) ZA200505114B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147019A (en) 2002-03-13 2012-10-15 Biogen Idec Inc Anti-alpha v beta 6 antibodies
US7276589B2 (en) 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
EP1755659B1 (en) 2004-03-24 2011-11-02 Abbott Biotherapeutics Corp. Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
US20060008415A1 (en) * 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
CN102875681A (zh) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
CA2646611A1 (en) * 2006-03-21 2008-05-22 Genentech, Inc. Combinatorial therapy
CN101448858B (zh) * 2006-03-21 2013-06-12 健泰科生物技术公司 牵涉α5β1拮抗剂的联合疗法
CA2652886A1 (en) * 2006-05-24 2007-11-29 Bayer Schering Pharma Aktiengesellschaft High affinity human and humanized anti-.alpha.5.beta.1 integrin function blocking antibodies with reduced immunogenicity
CN101563105B (zh) 2006-07-10 2013-01-23 拜奥根Idec马萨诸塞公司 用于抑制smad4-缺陷癌症的组合物和方法
EP2526967A1 (en) * 2007-07-17 2012-11-28 Merck Patent GmbH Engineered anti-alpha v-integrin hybrid antibodies
WO2009018226A2 (en) * 2007-07-27 2009-02-05 Facet Biotech Corporation Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e)
AR066170A1 (es) * 2007-09-26 2009-07-29 Genentech Inc Anti integrina alfa 5 beta 1
AU2009212442C1 (en) 2008-02-05 2014-07-17 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
KR101054725B1 (ko) * 2008-07-31 2011-08-05 재단법인서울대학교산학협력재단 세포외기질 성분을 함유하는 노화조절용 조성물 및 이를이용한 노화세포의 노화조절방법
CA2748161A1 (en) * 2008-12-23 2010-07-01 Astrazeneca Ab Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
US20120114667A1 (en) 2008-12-23 2012-05-10 Medimmune Limited TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
WO2010095031A2 (en) * 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
MA33210B1 (fr) * 2009-03-25 2012-04-02 Genentech Inc Nouveaux anticorps anti-a5b1 et leurs utilisations
CN101638429B (zh) * 2009-08-28 2012-01-25 南方医科大学 一种特异性识别细胞表面整合素α3β1的小分子肽
CA2784278C (en) * 2009-12-18 2019-02-26 Novartis Ag Wash solution and method for affinity chromatography
RU2015102845A (ru) * 2010-02-23 2015-06-10 Санофи АНТИТЕЛА К ИНТЕГРИНУ α2 И ИХ ПРИМЕНЕНИЯ
SG192667A1 (en) 2011-02-11 2013-09-30 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of prostate cancer
EP2834273B1 (en) * 2012-04-05 2018-08-22 F.Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
EP3530284B1 (en) 2012-12-26 2023-10-25 OncoSynergy, Inc. Anti-integrin beta1 antibody compositions and methods of use thereof
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
JP7414529B2 (ja) 2017-06-07 2024-01-16 シファメド・ホールディングス・エルエルシー 血管内流体移動デバイス、システム、および使用方法
EP3710076B1 (en) 2017-11-13 2023-12-27 Shifamed Holdings, LLC Intravascular fluid movement devices, systems, and methods of use
EP4085965A1 (en) 2018-02-01 2022-11-09 Shifamed Holdings, LLC Intravascular blood pumps and methods of use and manufacture
WO2020028537A1 (en) 2018-07-31 2020-02-06 Shifamed Holdings, Llc Intravascaular blood pumps and methods of use
US12220570B2 (en) 2018-10-05 2025-02-11 Shifamed Holdings, Llc Intravascular blood pumps and methods of use
WO2021011473A1 (en) 2019-07-12 2021-01-21 Shifamed Holdings, Llc Intravascular blood pumps and methods of manufacture and use
WO2021016372A1 (en) 2019-07-22 2021-01-28 Shifamed Holdings, Llc Intravascular blood pumps with struts and methods of use and manufacture
US12465748B2 (en) 2019-08-07 2025-11-11 Supira Medical, Inc. Catheter blood pumps and collapsible pump housings
WO2021062260A1 (en) 2019-09-25 2021-04-01 Shifamed Holdings, Llc Catheter blood pumps and collapsible blood conduits
US11724089B2 (en) 2019-09-25 2023-08-15 Shifamed Holdings, Llc Intravascular blood pump systems and methods of use and control thereof
US12102815B2 (en) 2019-09-25 2024-10-01 Shifamed Holdings, Llc Catheter blood pumps and collapsible pump housings
US12409310B2 (en) 2019-12-11 2025-09-09 Shifamed Holdings, Llc Descending aorta and vena cava blood pumps

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4704366A (en) * 1984-06-22 1987-11-03 Bio-Rad Laboratories, Inc. Process for binding IgG to protein A
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4801687A (en) * 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1992015683A1 (en) 1991-03-06 1992-09-17 MERCK Patent Gesellschaft mit beschränkter Haftung Humanized and chimeric monoclonal antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
KR100252547B1 (ko) 1991-09-05 2000-09-01 프레드 마리얀스키 폴리-또는 올리고누클레오티드의 세포로의 표적화된 전달
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
AU684041B2 (en) 1992-02-19 1997-12-04 Schering Corporation Cloning and expression of humanized monoclonal antibodies against human interleukin-4
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1995022618A1 (en) 1994-02-22 1995-08-24 Dana-Farber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5961955A (en) 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
AU746662B2 (en) * 1998-05-08 2002-05-02 Regents Of The University Of California, The Methods for detecting and inhibiting angiogenesis
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US7285268B2 (en) * 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device

Similar Documents

Publication Publication Date Title
JP2006516098A5 (enExample)
JP2007508034A5 (enExample)
JP2003515323A5 (enExample)
IL164966A0 (en) 3?-Ä2Z)-Ä1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylideneÜhydrazinoÜ-2'-hydroxy-Ä1,1'-biphenylÜ-3-carboxylic acid bis-(monoethanolamine)
WO2003093296A3 (en) Kinase anchor protein muteins, peptides thereof, and related methods
WO2003093306A3 (en) Nucleic acids and proteins from streptococcus groups a & b
EE200300100A (et) Polüpeptiid, selle kodeerivat nukleotiidjärjestust sisaldav nukleiinhape, vektor ja peremeesrakk, meetod polüpeptiidi valmistamiseks ning farmatseutiline kompositsioon
JP2005530695A5 (enExample)
JP2005529611A5 (enExample)
AU2003304180A8 (en) Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
CA2361987A1 (en) Goodpasture antigen binding protein
IS7609A (is) 2,5-tvíútskipt 3-merkaptópentansýra
JP2003284553A5 (enExample)
JP2006515984A5 (enExample)
AU2003223923A1 (en) Peptide nucleic acid conjugates with transporter peptides
JP2005535281A5 (enExample)
PL379564A1 (pl) Kwasy nukleinowe, proteiny i przeciwciała BTL-II
JP2008545719A5 (enExample)
JP2006510360A5 (enExample)
JPH10210974A5 (enExample)
ZA200100332B (en) Novel nucleotide sequences coding for the ptsH gene.
WO2001087932A3 (en) Seven transmembrane proteins and polynucleotides encoding the same
AU2003216772A1 (en) Nucleic acid molecule encoding a variant ddah 1 protein and uses thereof
RU2002110800A (ru) Искусственный белок-иммуноген TCI, содержащий множественные CTL-эпитопы основных антигенов ВИЧ-1, искусственный ген TCI, кодирующий полиэпитопный белок-иммуноген TCI
JP2004500045A5 (enExample)